RBC Capital analyst Brian Abrahams said weakness in Celgene (NASDAQ: CELG) related to a news article that discusses the departure ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE